MedTrace Logo

Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

NCT04687800 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-11-10

No results posted yet for this study

Summary

To monitor intraocular pressure in glaucoma patients after cataract surgery preformed in conjunction with minimally invasive glaucoma surgery (MIGS)

Conditions

  • Cataract

Interventions

DRUG

Dextenza 0.4mg intracanalicular Insert

intracanalicular insert delivery system

DRUG

Durezol 0.05% Ophthalmic Emulsion

Standard therapy, topical steroid drop

Sponsors & Collaborators

  • Ocular Therapeutix, Inc.

    collaborator INDUSTRY

  • Cathleen McCabe MD

    lead OTHER

Principal Investigators

  • Cathleen M McCabe, MD · The Eye Associates of Manatee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-10-24
Completion
2022-10-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04687800 on ClinicalTrials.gov